• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 203

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Pα+ Psychedelic Bulletin #218: FDA’s Farchione Says Psychedelic INDs Are “a Third” of Her Workload; Ipsos/Psychedelic Alpha Poll; Reunion Eyes Single Phase 3 in...

Joshua White – Fireside Project and Lucy, an AI Training Simulator for Psychedelic Support

Did New Jersey Really Just Legalize Psilocybin?

Psychedelic Funding, Public Markets, and M&A in 2025

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

PharmaDrug Announces Addition of Dr. Cindy Hutnik, President of the Canadian...

COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as...

Psychedelic Research Bulletin: November 2021

Psychedelic Bulletin: Our Dispatch from Horizons NYC; NIDA to Study Delix...

Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug...

Numinus Wellness Inc. Reports Q4 and Year End 2021 Results

Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke...

PsyBio Therapeutics Successfully Completes First Pre-IND Meeting with the United States...

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

PTSF88 – Dr. Ben Sessa of Awakn Life Sciences + Josh...

1...202203204...306Page 203 of 306

EDITOR PICKS

Pα+ Psychedelic Bulletin #218: FDA’s Farchione Says Psychedelic INDs Are “a...

Joshua White – Fireside Project and Lucy, an AI Training Simulator...

Did New Jersey Really Just Legalize Psilocybin?

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©